Overview Study of Testosterone and rHGH in FSHD Status: Active, not recruiting Trial end date: 2022-04-01 Target enrollment: Participant gender: Summary The purpose of this study is to investigate the safety and tolerability of combination therapy with recombinant human growth hormone (rHGH) and testosterone in adult male patients with facioscapulohumeral muscular dystrophy (FSHD) over 24 weeks. Phase: Phase 1 Details Lead Sponsor: University of RochesterTreatments: MethyltestosteroneTestosteroneTestosterone 17 beta-cypionateTestosterone enanthateTestosterone undecanoate